L. Thomas et al., 5-BROMO-2-DEOXYURIDINE REGULATES INVASIVENESS AND EXPRESSION OF INTEGRINS AND MATRIX-DEGRADING PROTEINASES IN A DIFFERENTIATED HAMSTER MELANOMA CELL, Journal of Cell Science, 105, 1993, pp. 191-201
Cell interactions with the extracellular matrix play a critical role i
n regulating complex processes such as terminal differentiation and tu
mor progression. In these studies we describe a melanoma cell system t
hat should be useful in addressing the regulation of cell-matrix inter
actions and the roles they play in regulating differentiation and cell
invasiveness. CS (suspension)-1 melanoma cells are relatively well di
fferentiated: they are melanotic, responsive to melanocyte-stimulating
hormone, and express TA99, a melanosome membrane differentiation mark
er. Their repertoire of integrin receptors for extracellular matrix li
gands is limited; in particular, they lack receptors for vitronectin,
accounting for the observation that they are nonadherent when cultured
in the presence of serum. CS-1 cells are non-invasive as well, and ex
press low levels of both metalloproteinases and activated plasminogen
activators. Treatment of these cells with melanocyte-stimulating hormo
ne causes them to increase melanin production and assume an arborized
phenotype, suggesting that it promotes their further differentiation.
In contrast, treatment of CS-1 with the thymidine analog 5-bromo-deoxy
uridine, converts them to a highly invasive cell population (termed BC
S-1) that loses its differentiated properties and responsiveness to me
lanocyte-stimulating hormone, acquires a broad integrin repertoire (in
cluding vitronectin receptors), and expresses elevated levels of metal
loproteinases and activated urokinase. From these observations and fin
dings of others on BrdU treatment of other developmental lineages, we
hypothesize that BrdU both suppresses differentiation and promotes inv
asiveness of CS-1 cells. The demonstrated manipulability of CS-1 cells
should make them extremely useful for studying the regulation of both
terminal differentiation and tumor progression in the melanocyte line
age.